Global Congenital Adrenal Hyperplasia Market 2025–2029: Competitive Insights and Opportunities
Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Expected Total Market Size Of The Congenital Adrenal Hyperplasia Industry By The Forecast Year 2029?
The market size for congenital adrenal hyperplasia has experienced significant growth in recent years. It is projected to expand from $0.47 billion in 2024 to $0.5 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.0%. This historical growth can be attributed to the increasing prevalence of congenital adrenal hyperplasia, the growing adoption of corticosteroid therapies, rising healthcare expenditure, an increasing focus on pediatric care, and an increase in government initiatives and reimbursement policies.
The market for congenital adrenal hyperplasia is projected to experience robust expansion over the coming years. Its valuation is anticipated to reach $0.65 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.9%. Factors contributing to this growth during the projected period include an escalating demand for personalized medicine, a higher occurrence of genetic disorders, intensified research into congenital adrenal hyperplasia treatments, increased investments in healthcare, and a greater adoption of telemedicine in managing congenital adrenal hyperplasia. Significant trends foreseen for the forecast period encompass improvements in healthcare infrastructure, progress in molecular diagnostics, the creation of enzyme replacement therapies, the formulation of long-acting corticosteroids, and breakthroughs in genetic screening.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21157&type=smp
What Are The Emerging Market Drivers Creating New Opportunities In The Congenital Adrenal Hyperplasia Industry?
The growing demand for gene therapy is expected to propel the expansion of the congenital adrenal hyperplasia market moving forward. Gene therapy is defined as a medical approach involving the modification or manipulation of an individual’s genes to treat or prevent illness. The heightened demand for gene therapy is attributed to advancements in genetic research and biotechnology, which have enabled more precise and targeted treatments for genetic disorders, cancers, and other chronic ailments. Congenital adrenal hyperplasia (CAH), a disorder caused by gene mutations responsible for adrenal hormone production, is a significant area of focus for gene therapy, offering opportunities for targeted genetic interventions to correct underlying genetic defects and restore normal hormone function. For instance, in April 2024, data from the American Society of Gene and Cell Therapy (ASGCT), a US-based professional membership organization, indicated that among the 1,023 gene therapies in development for rare diseases, eight of the top 10 rare diseases were oncological. The second quarter of 2024 also saw the initiation of 76 gene therapy trials, representing a 25% increase from the previous quarter. Therefore, the rising demand for gene therapy is driving growth in the congenital adrenal hyperplasia market.
How Is The Congenital Adrenal Hyperplasia Market Segmented?
The congenital adrenal hyperplasiamarket covered in this report is segmented –
1) By Type: Classic Congenital Adrenal Hyperplasia; Non-Classic Congenital Adrenal Hyperplasia
2) By Treatment And Diagnosis: Diagnosis; Treatment
3) By End-Use: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Research Institutes
Subsegments:
1) By Classic Congenital Adrenal Hyperplasia: Salt-Wasting Classic Congenital Adrenal Hyperplasia; Simple Virilizing Classic Congenital Adrenal Hyperplasia
2) By Non-Classic Congenital Adrenal Hyperplasia: Late-Onset Non-Classic Congenital Adrenal Hyperplasia; Mild Non-Classic Congenital Adrenal Hyperplasia
How Are Emerging Market Trends Shaping The Congenital Adrenal Hyperplasia Industry Landscape?
Major companies in the congenital adrenal hyperplasia market are focusing on developing innovative treatments like CRF1 receptor antagonists to regulate cortisol production and reduce adrenal androgen excess. A CRF1 receptor antagonist is a drug that blocks the corticotropin-releasing factor 1 (CRF1) receptor to manage the body’s stress response and decrease excessive adrenal androgen production in conditions such as congenital adrenal hyperplasia. For instance, in December 2024, Neurocrine Biosciences, Inc., a US-based biopharmaceutical company, received FDA approval for crenessity (crinecerfont), which is the first new treatment for congenital adrenal hyperplasia (CAH) in 70 years. This oral medication acts as a selective antagonist of corticotropin-releasing factor type 1 receptors, helping to control excess adrenocorticotropic hormone (ACTH) and adrenal androgens while allowing for reduced glucocorticoid doses. The approval was based on data from the CAHtalyst Phase 3 studies, which demonstrated significant efficacy in lowering androgen levels. Crenessity is expected to be available soon, representing a significant advancement in CAH management.
Which Key Market Players Are Investing In Expansion And Innovation Of Congenital Adrenal Hyperplasia Market?
Major companies operating in the congenital adrenal hyperplasia market are Pfizer Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Eton Pharmaceuticals Inc, Teva Pharmaceutical Industries, Macleods Pharmaceuticals, H. Lundbeck A/S, Neurocrine Biosciences Inc., BridgeBio Pharma Inc, Regenxbio Inc., Millendo Therapeutics Inc., Applied Therapeutics, Inc., OMass Therapeutics Limited, ViennaLab Diagnostics GmbH, EffRx Pharmaceuticals SA, Adrenas Therapeutics Inc, HBM Alpha Therapeutics, Spruce Biosciences Inc., Crinetics Pharmaceuticals Inc.
Download The Full Report For Exclusive Market Findings:
Which Regional Markets Are Contributing Most To The Congenital Adrenal Hyperplasia Industry Expansion?
North America was the largest region in the congenital adrenal hyperplasia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congenital adrenal hyperplasia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Congenital Adrenal Hyperplasia Market Report:
https://www.thebusinessresearchcompany.com/customise?id=21157&type=smp
Browse Through More Reports Similar to the Global Congenital Adrenal Hyperplasia Market 2025, By The Business Research Company
Congenital Diaphragmatic Hernia Drugs Global Market Report 2025
Benign Prostatic Hyperplasia Bph Treatment Devices And Equipment Global Market Report 2025
Adrenal Cancer Diagnostics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/adrenal-cancer-diagnostics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
